Form 4: Lexeo Therapeutics Executive Sandi See Tai Reports Acquisition of Stock Options and Restricted Stock Units

Chief Development Officer Sandi See Tai reports the acquisition of stock options and restricted stock units in Lexeo Therapeutics.

Summary

• On January 7, 2025, Sandi See Tai, Chief Development Officer of Lexeo Therapeutics, reported the acquisition of 38,750 restricted stock units (RSUs) and stock options for 77,500 shares.
• The RSUs vest in installments starting February 15, 2026, with 25% vesting initially and the remainder vesting quarterly.
• The stock options vest starting January 7, 2026, with 25% vesting initially and the remainder vesting monthly.
• The exercise price for the stock options is $7.33.
• Following these transactions, Tai directly owns 55,375 shares of common stock and stock options for 77,500 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options and RSUs by a key executive is generally a positive sign, indicating confidence in the company's future. However, it's a routine transaction.

Positives

• The acquisition of RSUs and stock options by a key executive signals confidence in the company's future performance.

Future Outlook

The vesting schedules for the RSUs and stock options incentivize continued service and alignment with the company's long-term success.

Industry Context

Insider transactions are closely monitored as indicators of management's sentiment regarding the company's prospects within the biotechnology industry.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates